• Amneal won FDA clearance for new strengths and vial sizes of iohexol injection, expanding its generic OMNIPAQUE-referenced contrast portfolio.
• Launch targeted for Q3 2026; the company expects broader coverage of US demand across key hospital and imaging-center presentations.
• IQVIA estimates US annual iohexol injection sales at about $706 million for the 12 months ended May 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607170800PRIMZONEFULLFEED9763692) on July 17, 2026, and is solely responsible for the information contained therein.